

When infants fail to thrive

Diarrhoea, vomiting, dehydration and weight loss mean intravenous feeding to restore the fluid and electrolyte balance.

Diagnosis and management mean the Mead Johnson Nutritional Feeding System.

PREGESTIMIL*

Glucose, M.C.T. and protein hydrolysate formula

first line dietary formulation.
complete feed in easily assimilated basic form for test feeding.
sucrose free for sucrose intolerance.

NUTRAMIGEN*

Protein hydrolysate formula

complete feed for infants with intact protein intolerance.
for the dietary management of galactosaemia.

PROSOBEE*/SOBEE*

Milk free soy formula



milk substitute for infants sensitive to milk protein.
milk free formula for infants allergic to milk.

PORTAGEN*

Nutritionally complete dietary

complete formula containing medium chain triglycerides for infants with fat malabsorption.
lactose free for lactose intolerance.

Mead Johnson feeds are formulated to provide complete vitamin and mineral supplements for the management of malabsorption or intolerance conditions in infants.



Mead Johnson NUTRITIONAL FEEDING SYSTEM

A comprehensive feeding programme for infants who fail to thrive

Further information is available from:



Bristol Laboratories, Division of Bristol-Myers Co Ltd, Stamford House, Langley, SLOUGH SL3 6EB.

*Trade Mark ©1975




The tasteful way to treat ORAL THRUSH

The specially formulated viscous base enables increased contact with the affected area to be maintained.

Nystatin – the proven treatment for oral *Candida albicans* infections.

DOME is a trade mark



Nystatin-Dome ORAL SUSPENSION

Full information available on request.

Dome Laboratories




Division of Miles Laboratories Ltd

Stoke Court Stoke Poges Slough SL2 4LY Tel Farnham Common 2151

DM 662

Normal plate demonstrating staphylococcal sensitivity to various antibiotics. The left hand side of the plate has been streaked with penicillinase.

Cephadrine (Squibb Velosef) alone remains fully active.



VELOSEF

reduces the risk of antibiotic failure

Many organisms, whether present as pathogens or commensals, can produce penicillinase which destroys any penicillin or ampicillin present.

Velosef has a truly broad spectrum of activity and bactericidal action, including activity against penicillinase-producing organisms and the main causative organisms in bronchitis.

in chest infections in adults and children

R_x VELOSEF first time
for fast reliable results without complications

VELOSEF[®] is Squibb cephradine capsules and syrup.

Further information on request from:
E. R. Squibb & Sons Limited, Regal House, Twickenham, Middlesex, TW1 3QT.



Zeitschrift für **Kinder—
heilkunde**
Journal of Pediatrics

Band 120 Heft 3 1975

- 151 **E. F. Gilbert, J. Varakis, J. M. Opitz, G. M. Zur Rhein, R. Ware, C. Viseskul, E. G. Kaveggia, H. A. Hartmann:** Generalized Gangliosidosis Type II (Juvenile GM₁ Gangliosidosis). A Pathological, Histochemical and Ultrastructural Study
- 181 **I. Lombeck, H. G. Schnippering, K. Kasperek, F. Ritzl, H. Kästner, L. E. Feinendegen, H. J. Bremer:** Akrodermatitis enteropathica — eine Zinkstoffwechselstörung mit Zinkmalabsorption
Acrodermatitis enteropathica — A Disturbance of Zinc Metabolism with Zinc Malabsorption
- 191 **G. Neuhäuser, E. G. Kaveggia, J. M. Opitz:** Studies of Malformation Syndromes of Man XXXVIII: The BD Syndrome. A "New" Multiple Congenital Anomalies/Mental Retardation Syndrome with Athetoid Cerebral Palsy
- 199 **M. Fieber, R. Meschede, W. Tolckmitt:** Acidität und peptische Aktivität des Magensafts bei gesunden und Mucoviscidosis-kranken Kindern
The Acidity and Peptic Activity of Gastric Juice in Healthy Children and in Children Suffering from Cystic Fibrosis
- 211 **J. Ritter, G. Gaedicke, K. Winkler, G. Landbeck:** Immunologische Oberflächenmarker von Lymphoblasten bei der saure Phosphatase-positiven akuten Leukämie
Immunological Cell Markers on Lymphoblasts of Patients with Acid Phosphatase Positive Acute Leukemia
- 217 **F. Herz, E. Kaplan, E. S. Scheye:** A Longitudinal Study of Red Cell Enzymes in Infants of Low Birth Weight
- 223 **F. Majewski, M. A. Kim, W. F. Haberlandt, H. M. Niemczyk:** Reziproke Translokation $t(5p-;19p+)$ in 3 Generationen
Reciprocal Translocation $t(5p-;19p+)$ in Three Generations

Indexed in Current Contents



Springer-Verlag
Berlin · Heidelberg · New York



Rivotril is effective in the treatment of petit mal,¹ atypical petit mal,² myoclonic epilepsy³ and hypsarrhythmia⁴ and status epilepticus.⁵ It is also useful in the treatment of grand mal⁶ and temporal lobe epilepsy.⁶

Like other benzodiazepines, Rivotril is relatively non-toxic⁶ and exhibits comparatively few systemic side-effects.⁴⁻⁶

Rivotril is an important advance in the anticonvulsant therapy of *all* clinical forms of epileptic disease.

1. *Acta Neurol Scand*, 1973, 49(Suppl 153), 82
2. *Acta Neurol Scand*, 1973, 49(Suppl 153), 26
3. *Developmental Child Neurology*, 1972, 14, 3
4. *Epilepsia*, 1971, 12, 157
5. *Acta Neurol Scand*, 1973, 49(Suppl 153), 91
6. *S. Afr. med. J.*, 1973, 77, 1683



RIVOTRIL

Anticonvulsant

Rivotril is the trade name for the anticonvulsant preparation containing clobazam

For further information, contact the manufacturer

Roche Products (UK) Limited, Welwyn Garden City, Herts. AL9 1AT

© 1974

In pituitary dwarfism

CRESCORMON[®]

human growth hormone

Crescormon is a highly purified preparation of human pituitary growth hormone thoroughly tested for homogeneity and potency.

Substitution therapy with Crescormon in patients suffering from GH deficiency leads to an acceleration of growth. The therapy is safe and no resistance to treatment has been reported.

Crescormon is standardized both by radio-immunological determination and by biological assay. Each vial contains 4 IU determined against IRP Growth Hormone (WHO).

Indications

Dwarfism due to decreased or failed secretion of pituitary growth hormone. The diagnosis should be verified before the preparation is administered by an investigation of the pituitary function.

Contraindication

Diabetes mellitus.

Precautions

In spite of rigorous requirements for the collection and careful control of the pituitary glands used in the preparation of Crescormon, the risk of transmitting hepatitis cannot be excluded. The risk may be considered extremely small, however, and no cases have as yet been reported.

Side Effects

In clinical trials Crescormon has elicited the formation of antibodies in low titre in a few patients, which, however, has not affected the growth rate. Otherwise no adverse reactions have been observed.

Dosage

The dosage is individual, but in general a dose of at least 0.5 IU per kg body weight per week, divided into two to three intramuscular injections, is recommended.

Administration

Crescormon should be injected intramuscularly. The solution for injection is prepared by adding 2 ml Sodium Chloride Injection to the lyophilized substance in the vial. A made-up solution should be used immediately after preparation.

Storage

Refrigerator (+5° C).

Pack

Crescormon combined package of lyophilized sterile HGH 4 IU (about 2 mg) and Sodium Chloride Injection in an ampoule of 2 ml.

Product Licence No. 0022/0020

KabiVitrum

KabiVitrum Limited,
Bilton House,
Uxbridge Road,
London W5 2TH
Telephone: 01-567 4717 01-579 1871

Outside U.K. information and supplies are available from the respective Kabi representative or directly from AB Kabi, Fack, S-104 25 Stockholm, Sweden.

Septrin b.d. in otitis media



better for him better for mum

Better for him because Septrin has a powerful activity against the causative pathogens ensuring a rapid response and high success rates.^{1,2}

Better for mum because the twice-daily dosage of Septrin removes the worry of giving medicine at awkward times of the day and night.

1 *J infect Dis*, (1973), 128, suppl, 629. 2 *Canad med Ass J*, (1975), 112, 87S.

Septrin contains trimethoprim and sulphamethoxazole.
FULL PRESCRIBING INFORMATION IS AVAILABLE ON REQUEST.
Wellcome Medical Division, The Wellcome Foundation Ltd., Berkhamsted, Herts



Wellcome

SEPTRIN

TRADE MARK

Monatsschrift für Kinder- heilkunde

Organ der Deutschen Gesellschaft für Kinderheilkunde

123. Band · Heft 8 · August 1975

Zur 72. Jahrestagung
der Deutschen Gesellschaft
für Kinderheilkunde
vom 8. bis 10. 9. 1975 in München

Originalien

- H. von der Hardt, W. Meiser
B.-K. Jüngst
Allergentestungen beim kindlichen Asthma bronchiale
(Allergentesting in Children with Asthma Bronchiale) 577
- Das klinische Bild des rheumatischen Fiebers heute
(The Changing Clinical Pattern of Rheumatic Fever) 588
- R. Urbaneck, I. Witt, D. Karitzky
Hypophosphatämie als Frühzeichen der Sepsis im Kindesalter
(Hypophosphataemia as Early Sign of Septicaemia in Childhood) 593
- M. W. Köllermann, H. Scherf, D. Schwärke, H. Klosterhalfen
Familiärer vesico-ureteraler Reflux und familiäre Infektanfälligkeit
(Familial Vesico-Ureteral Reflux and Familial Urinary Tract Infection) 598

Fortbildung und Praxis Übersichten

- Aktuelle Probleme auf dem Gebiet der kindlichen Hepatitiden. Podiumsdiskussion, gehalten auf der 71. Tagung der Deutschen Gesellschaft für Kinderheilkunde in Hamburg am 10. 9. 1974
- M. Neidhardt
Einführung 603
- F. K. Kößling
D. Feist
Pathologische Anatomie kindlicher Hepatitiden 604
- K. H. Meyer zum Büschenfelde, W. Arnold
Aktuelle Labordiagnostik bei kindlichen Hepatitiden 609
- S. Seidl
Neuere Erkenntnisse über das Hepatitis B-Antigen 617
- S. W. Bender, V. v. Loewenich, K. Hübner
Neonatale Hepatitis 621
- R. Ortlieb
Was leistet die medikamentöse Behandlung bei kindlicher Hepatitis? 626
- Th. Lücking
Was leistet die diätetische Behandlung bei kindlicher Hepatitis? 628
- W. Baumann
Indikationen und Ergebnisse immunsuppressiver Therapie bei chronisch aktiver Hepatitis im Kindesalter 630

Buchbesprechungen 633 · Tagesgeschichte 636

Indexed in Current Contents



Eine spanische Ausgabe dieser Zeitschrift erscheint bei Editorial Lectura y Estudio, S. A., Barcelona

Monatsschrift
für Kinderheilkunde

Springer-Verlag Berlin Heidelberg New York

MOKIAY 123 (8) 577-636 (1975)

PEDIATRIC RESEARCH

Volume 9, No. 6

June 1975

Contents

Hemopexin Synthesis *in Vitro* by Human Fetal Tissues

U. MULLER-EBERHARD, H. H. LIEM, K. H. COX, AND T. P. CONWAY (La Jolla, California)

The concentration of hemopexin, albumin, and transferrin in fetal serum and the amount of these proteins synthesized by fetal tissues is determined by these investigators, who found significant synthesis of hemopexin and albumin only in the liver.

α -Ketoaciduria: A Description of a New Metabolic Error in Lysine-Tryptophan Degradation

R. W. WILSON, C. M. WILSON, S. C. GATES, AND J. V. HIGGINS (East Lansing, Michigan)

These investigators describe a mentally retarded male with elevated levels of α -aminoacidic and α -ketoacidic acids in his urine; their results suggest a new inborn error of metabolism involving the catabolism of lysine and tryptophan.

Fetomaternal Potassium Relations in the Fetal Rat of Twenty Days of Gestational Age

A. G. FANTEL (Seattle, Washington)

Studies undertaken by this scientist demonstrate that potassium concentrations in fetal rat plasma are considerably lower than those in maternal plasma; the fetal plasma levels are consistent with predictions based upon a passive transfer model.

Leukocyte Urea Cycle Enzymes in Hyperammonemia

D. M. WOLFE AND P. D. GATFIELD (London, Ontario, Canada)

Blood from patients with three hepatic urea cycle disorders was studied by these investigators who found that analysis of urea cycle enzymes in leukocytes may be useful in disease detection.

Interaction of Endogenous Growth Hormone, Cortisol, and Catecholamines with Blood Glucose in Children with Brittle Diabetes Mellitus

E. BRUCK AND M. H. MACGILLIVRAY (Buffalo, New York)

These studies document the sequences of hypoglycemia followed by hyperglycemia in diabetic children in response to excessive production of growth hormone and other antagonists of insulin; prompted by hyperglycemia, increasing administration of exogenous insulin results in a vicious cycle of hypoglycemia alternating with hyperglycemia (Somogyi syndrome).

The Use of Transfer Factor in a Patient with Agammaglobulinemia

N. M. ZALDIVAR, P. S. PAPA-GEORGIOU, S. KAFFE, AND P. R. GLADE (New York, New York)

Transfer factor therapy is used by these workers in an attempt to alter the clinical course of a patient with agammaglobulinemia; their findings suggest that transfer factor may affect immunoglobulin synthesis.

The Effect of Increased Pulmonary Blood Flow on the Pulmonary Vascular Bed in Pigs

B. FRIEDLI, G. KENT, AND B. S. L. KIDD (Toronto, Canada)

Obligatory shunts in 1-month-old piglets were produced by these scientists by unilateral pneumonectomy, creation of systemic arteriovenous fistulas, or a combination of both in an attempt to identify changes in the pulmonary vasculature induced by high pulmonary blood flow.


Citrullinemia: Enzymatic Evidence for Genetic Heterogeneity

N. G. KENNAWAY, P. J. HARWOOD, D. A. RAMBERG, R. D. KOLER, AND N. R. M. BUIST (Portland, Oregon)

The *in vitro* activity and kinetic properties of argininosuccinate synthetase were examined by these authors in three patients with citrullinemia.

Metabolic Aspects of Disease

Treatment of inborn errors has advanced our basic knowledge of disease. Metabolic problems are also a frequent consequence of disease.



Day-time variations in serum phenylalanine (triangles) and tyrosine (circles) in a phenylketonuric child having his first meal as usual at 07.45 hours or fasting until 11.45 hrs. Note the phenylalanine depressing effect of the breakfast (phenylalanine-restricted meal with Albumaid (R) (Güttler, Olesen & Wamberg—Kennedy Institute—Denmark in Enzymopenic Anaemias, Lysosomes and other papers, pages 149-158 E. & S. Livingstone.)

PRECISION PRODUCTS:

Designed to meet the metabolic defect are called for.

Products more fundamental than enzymes.

Products more basic than protein.

Products which enable precise nutrition.

Products which succeed where cows' milk is a failure.

PRECISION PRODUCTS FOR:

Phenylketonuria, Homocystinuria, Cystinosis, Maple Syrup Urine Disease, Hyperglycinaemia, Hyperprolinaemia, Arginine Succinic Urea, Histidinaemia, Tyrosinosis, Carbohydrate and Protein Intolerance, Malabsorptions, Cystic Fibrosis, Glycogen Storage Disease.

MILNER SCIENTIFIC AND MEDICAL RESEARCH

Now maintains a world-wide interest in every aspect of metabolism in disease, and products are directly available in most countries.

For further details please write to Sole U.K. Agents:

SCIENTIFIC HOSPITAL SUPPLIES LTD.
38 QUEENSLAND STREET, LIVERPOOL 7